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Abstract
Introduction: X-linked adrenoleukodystrophy (X-ALD) is a complex disorder with variable expressivity that affects
the nervous, adrenocortical and male reproductive systems. Although ABCD1 mutations are known to provide the
genetic basis for X-ALD, its pathogenesis is not fully elucidated. While elevated very long chain fatty acid (VLCFA)
levels in blood and reduced VLCFA catabolic activity in cultured fibroblasts are biomarkers used to identify ABCD1
mutation carriers, the roles peroxisomal lipid metabolism play in disease etiology are unknown.
Methods: Primary skin fibroblasts from two male patients with the childhood cerebral form of the disease (CCALD)
caused by ABCD1 frameshift or missense mutations and three healthy donors were transduced with retroviral
vectors expressing the OCT4, SOX2, KLF4 and c-MYC factors. Candidate induced pluripotent stem cells (iPSCs) were
subject to global gene expression, DNA methylation, DNA copy number variation, and genotyping analysis and
tested for pluripotency through in vitro differentiation and teratoma formation. Saturated VLCFA (sVLCFA) and
plasmalogen levels in primary fibroblasts and iPSCs from healthy donors as well as CCALD patients were
determined through mass spectroscopy.
Results: Skin fibroblasts from CCALD patients and healthy donors were reprogrammed into validated iPSCs. Unlike
fibroblasts, CCALD patient iPSCs show differentially expressed genes (DEGs) relevant to both peroxisome
abundance and neuroinflammation. Also, in contrast to fibroblasts, iPSCs from patients showed no significant
difference in sVLCFA levels relative to those from controls. In all cell types, the plasmalogen levels tested did not
correlate with ABCD1 mutation status.
Conclusion: Normal ABCD1 gene function is not required for reprogramming skin fibroblasts into iPSCs or
maintaining pluripotency. Relative to DEGs found in fibroblasts, DEGs uncovered in comparisons of CCALD patient
and control iPSCs are more consistent with major hypotheses regarding disease pathogenesis. These DEGs were
independent of differences in sVLCFA levels, which did not vary according to ABCD1 mutation status. The
highlighted genes provide new leads for pathogenic mechanisms that can be explored in animal models and
human tissue specimens. We suggest that these iPSC resources will have applications that include assisting efforts
to identify genetic and environmental modifiers and screening for therapeutic interventions tailored towards
affected cell populations and patient genotypes.
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Introduction
X-linked adrenoleukodystrophy (X-ALD) is a complex
disorder caused by mutations in the ABCD1 gene that
encodes an integral peroxisome membrane protein
belonging to the ATP-binding cassette transporter
superfamily [1-4]. X-ALD primarily affects the nervous
system, adrenal cortex and testes with highly variable
clinical presentations that are influenced by modifier
genes and the environment [2,3]. Males with ABCD1
mutations develop childhood cerebral ALD (CCALD)
about 33% of the time and adult onset adrenomyelo-
neuropathy (AMN) about 45% of the time [2,3]. CCALD
patients typically show symptoms between five and nine
years of age with rapid cerebral demyelination and adre-
nocortical atrophy. Within a few years of onset, they
suffer dementia and progressive neurological deficits
that eventually lead to death. In contrast, AMN patients
show a later onset of disease (20 to 40 years of age) and
present with adrenal insufficiency, a distal axonopathy
in the spinal cord and peripheral neuropathy that results
in progressive spastic paraparesis with debilitating end
stage disease [2,3]. Approximately 10% of hemizygotes
develop primary adrenocortical insufficiency (Addison’s
disease) with no evidence of nervous system dysfunction
[2,3]. Disease prognosis is challenging since mutations
do not correlate with clinical phenotypes [5] and male
siblings with the same ABCD1 mutation, including
monozygotic male twins [6,7], can have dramatically dif-
ferent clinical presentations [8]. Although hemizygotes
typically show the most severe clinical manifestations of
disease, about half of female ABCD1 mutation carriers
develop AMN-like symptoms later in life [2,3].
The molecular mechanisms underlying the inflamma-
tory brain demyelination found in CCALD patients are
not fully understood. It has been hypothesized to be
related to the accumulation of saturated very long chain
fatty acids (sVLCFAs) in specific central nervous system
(CNS) cell types (for example, oligodendrocytes and
microglial cells) and/or lipid classes (for example, gang-
lioside, phosphatidylcholine and cholesterol ester frac-
tions) [9-11]. Other hypotheses have focused on the roles
of oxidative stress [12-16], myelin sheath integrity [17],
oligodendrocyte apoptosis and microglial cell activation
[1,2], and CNS cell membrane receptors [18].
Here, we report the generation and genomic characteri-
zation of CCALD patient-specific induced pluripotent stem
cell (iPSC) model systems that can provide a platform to
investigate cell autonomous processes relevant to X-ALD
pathogenesis. The gene expression and biochemical profiles
of these patient-specific iPSCs provide a novel perspective
that supports the leading hypotheses regarding disease
pathogenesis. Furthermore, our resources provide a first
step required for the development and interpretation of
patient-specific model systems that investigate genetic
modifiers, environmental risk factors and non-cell autono-
mous processes relevant to the etiology of X-ALD.
Materials and methods
Cell culture conditions
Primary dermal fibroblast cultures from CCALD
patients and controls were obtained from the Peroxiso-
mal Disease Laboratory at the Kennedy Krieger Institute
and Coriell Institute Cell Repositories, respectively. All
cells described herein were cultured at 37°C with 5%
CO2. Human primary dermal fibroblasts and mitomycin
inactivated mouse embryonic fibroblasts (MEFs) were
cultured in fibroblast media (DMEM supplemented with
10% FBS, L-glutamine, penicillin/streptomycin, vitamin
solution, and essential and nonessential amino acids
(Life technologies, Foster City, CA, USA)), as previously
described [19]. iPSCs were cultured on a layer of mito-
mycin C-inactivated MEF feeder cells in iPSC medium
(DMEM:F12 medium supplemented with 20% KSR,
L-glutamine, penicillin/streptomycin, nonessential amino
acids, b-mecaptoethanol and bFGF (Life technologies,
Foster City, CA, USA)) [20,21].
Cell reprogramming
Five different pMX retroviral vectors designed to deliver
green fluorescent protein (GFP) and human OCT4,
SOX2, KLF4 and C-MYC cDNA sequences were obtained
from Addgene (Cambridge, MA, USA) [20,21]. Primary
human fibroblasts were twice transduced with a mixture
of all five retroviruses as described [20,21]. Transduction
efficiency was evaluated by GFP expression. After four
days, cells were re-plated onto MEF feeders and cultured
in hESC medium containing 1 mM valproic acid [22]. By
four weeks, candidate iPSC colonies were manually
picked and clonally expanded [20,21]. A full list of the
analyses conducted on each of the candidate iPSCs is
described below and provided in Additional file 1.
Protein pluripotency biomarker analysis
Alkaline phosphatase staining was performed using the
leukocyte alkaline phosphatase kit (Sigma-Aldrich,
St. Louis, MO, USA). For immunostaining, cells were
fixed in 4% paraformaldehyde for 20 minutes, permeabi-
lized with 1% Triton X-100 for 5 minutes except for sur-
face marker staining, and blocked in 1% BSA in 1 × PBS
for 1 hour at room temperature. Primary antibody stain-
ing was performed at 4°C overnight with antibodies
against OCT4 and NANOG (goat polyclonal IgG against
human, R&D Systems, Minneapolis, MN, USA), SOX2
(goat polyclonal IgG against mouse, rat and human) and
SSEA4 (mouse monoclonal IgG3 against human, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), TRA-1-60
(mouse monoclonal IgM against human, Millipore, Bill-
erica, MA, USA), TuJ1 (rabbit monoclonal IgG1 against
Wang et al. Stem Cell Research & Therapy 2012, 3:39
http://stemcellres.com/content/3/5/39
Page 2 of 15
mammalian, Covance Research Products, Princeton, NJ,
USA), a-SMA (mouse monoclonal IgG2a against human,
mouse and so on, Sigma-Aldrich, St. Louis, MO, USA),
and AFP (mouse monoclonal IgG2a against human, pig
and canine, Life technologies, Foster City, CA, USA). Sec-
ondary antibody staining was performed at room tem-
perature for one hour with appropriate fluorescence
conjugated secondary antibodies from Life technologies,
Foster City, CA, USA and Jackson ImmunoResearch,
West Grove, PA, USA. Nuclei were visualized by staining
with 100 ng/ml DAPI (Life technologies, Foster City, CA,
USA).
Gene expression profiling
Total RNA samples (100 ng per sample) were converted
into biotin-labeled cRNA targets (Affymetrix GeneChip®
IVT Labeling Kit, Santa Clara, CA, USA), processed and
analyzed on Affymetrix Human Genome 133A 2.0 or 133
Plus 2.0 GeneChips, as previously described [19]. Using
WebArray software (San Diego, CA, USA), we applied
the RMA algorithm to generate log2-transformed gene
expression values and linear model statistical analysis
(limma) to identify differentially expressed genes (DEGs)
with false discovery rates (FDRs) calculated using the
spacings LOESS histogram (SPLOSH) method [23,24]
(Additional file 2). We performed hierarchical clustering
analysis using Partek Genomics Suite software (St. Louis,
MO, USA). We conducted GeneOntology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analyses using WebGestalt software (Nashville,
TN, USA) [25-27]. We used the DAVID (Database for
Annotation, Visualization and Integrated Discovery) v6.7
bioinformatics resource [28] for the annotation of gene
functions. Scaled gene expression scores and .cel files are
available at the National Center for Biotechnology Infor-
mation (NCBI) Gene Expression Omnibus (GEO) reposi-
tory under Series Accession Number GSE34308.
DNA methylation profiling
Genomic DNA was extracted from cultured cells as
described [29,30] and analyzed on 450 K Infinium Methy-
lation BeadChips (Illumina, San Diego, CA, USA), which
interrogate the methylation status of over 485,000 CpG
sites distributed across the human genome. The resulting
data were analyzed using GenomeStudio software (that is,
unmethylated to fully methylated) for each locus (Addi-
tional file 3). Bisulfite DNA sequencing was conducted as
previously described [29,30].
Genotyping and copy number analysis
Genomic DNA from cultured cells was also analyzed
using Human CytoSNP-12 Infinium HD BeadChips (Illu-
mina) that interrogate the genotypes of 299,140 human
single nucleotide polymorphisms (SNPs). Data filtering
and analysis were performed in GenomeStudio (Illu-
mina). Copy number analysis was performed using
CNVPartition version 2.4.4 with a confidence threshold
set at 50 and a minimum of 10 SNP probes per CNV
region, as previously described [31]. In multiple samples,
we performed the global genotyping analysis two inde-
pendent times and only assigned a copy number change
(CNC) if both analyses were in agreement (Additional
file 4). Dideoxysequencing of ABCD1 exons 1, 8 and 9
was performed as previously described [32,33].
In vitro differentiation and teratoma assays
iPSCs were detached from culture dishes with collagenase
IV, maintained in suspension to induce embryoid body
(EB) formation and subjected to an in vitro differentiation
procedure, as described [34,35]. For teratoma analysis,
iPSCs from a confluent 10 cm2 plate were harvested and
subcutaneously injected to the dorsal flanks of immunode-
ficient (SCID) mice (Jackson Laboratory, Bar Harbor, ME,
USA), as described [34]. Nine weeks after injection, terato-
mas were excised, fixed in 10% formalin, sectioned and
stained with hematoxylin and eosin.
Lipid analysis
We used liquid chromatography-tandem mass spectrome-
try (LC-MS/MS) to measure C26:0-lysophosphorylcholine
and phosphatidylethanolamine (PE) plasmalogen levels in
cell lysates processed by methanol extraction as described
in reference [36]. Herein, C26:0-lysophosphorylcholine
measurements were used to evaluate VLCFA levels. The
tetradeuterated analog of 1-O-hexadecyl-2-lysn-sn-3 phos-
phorylcholine was used to quantify PE plasmalogens. PE
plasmalogens were identified based on the fragmentation
patterns reported in reference [37].
Results
Derivation of candidate iPSCs from CCALD patient
fibroblasts
Primary skin fibroblast cultures from three healthy donors
and two CCALD patients (Table 1) were infected with ret-
roviruses designed to express the human OCT4, SOX2,
KLF4 and c-MYC genes (Methods). We observed iPSC-
like colonies for two weeks and clonally expanded TRA-1-
60 positive colonies for four weeks, consistent with prior
reports of reprogramming skin fibroblasts from healthy
human donors [38]. All candidate iPSC colonies main-
tained the expected morphological features and expressed
protein biomarkers of pluripotency (Figure 1A, Additional
file 1).
Genotypes and DNA copy number profiles of iPSCs
We confirmed that the patient iPSCs had the expected
mutant ABCD1 genotypes and that control iPSCs lacked
these specific ABCD1 mutations by dideoxysequencing.
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As determined by BeadArray analysis, the genotypes of
over 290,000 SNPs in iPSCs and original fibroblasts
were > 99.9% concordant. Based on the same genotyping
data, we did not detect copy number changes (CNCs,
that is, insertions or deletions greater than 10-kb
in length) in patient CCALD1-1, CCALD1-2 and
CCALD2-1 iPSCs or Control1-3, Control1-4 and Con-
trol2-1 iPSCs (Additional file 4). Consistent with prior
reports of reprogrammed human cells [39-41], we
detected CNCs in 8/14 (57%) iPSCs analyzed (Addi-
tional file 4). These iPSCs had one (CCALD1-3,
CCALD1-4 and Control2-3), two (Control1-2 and Con-
trol3-1), three (Control2-2 and Control2-4) or five (Con-
trol1-1) separate genomic regions affected by a CNC
(Additional file 4).
Gene expression profiles of CCALD and control donor
cells
We validated the robust expression of previously reported
iPSC signature genes in control and CCALD donor-
derived iPSCs and skin fibroblasts [38] based on a subset
of the data generated from global expression profiling of
over 18,000 transcripts (Figure 2A). Unsupervised hier-
archical clustering analysis based on the expression of pre-
selected pluripotency biomarkers or the most variable
transcripts (that is, coefficient of variation (CV) > 0.10
across all samples)) produced two distinct clusters consist-
ing of skin fibroblasts and the iPSCs (Figure 1 and Addi-
tional file 5).
DNA methylation profiles of CCALD and control donor
cells
We performed global DNA methylation analysis interro-
gating over 485,000 CpG sites of all starting fibroblast
cultures and reprogrammed iPSCs (Table 1) (Methods).
Hierarchical clustering analysis demonstrated that the
iPSCs and fibroblasts have distinct DNA methylation
profiles that were independent of ABCD1 mutation status
(Figure 2B).
In vitro differentiation of CCALD patient iPSCs and in vivo
teratoma formation
All control and CCALD patient-derived iPSCs subjected
to in vitro embryoid body assays produced cells derived
from all three germ layers (Methods) (Figure 1B).
Furthermore, all three iPSCs tested (one control and
two CCALD patient donors) formed teratomas when
injected into immune-deficient mice (Methods). In all
these teratomas, histological analysis demonstrated the
presence of tissues representative of all three germ
layers (Figure 1C).
Comparative lipid profiling of cells from healthy donors
and those with CCALD
Consistent with prior reports [42], cultured CCALD
patient skin fibroblasts grown in fibroblast growth media
showed 4.3-fold elevated VLCFA levels (based on C26:0-
lysophosphorylcholine measurements, see Materials and
methods), but similar PE plasmalogen levels relative to
fibroblasts from healthy donors (Figure 3A, C)). Similarly,
we found 3.8-fold elevated VLCFA levels, but comparable
PE plasmalogen levels, in patients relative to control fibro-
blasts grown under the same conditions in iPSC media
(Figure 3A, C). In contrast, no significant differences were
found for either VLCFA or PE plasmalogen levels in
patient and control iPSCs cultured under the same condi-
tions in iPSC media (Figure 3). Nevertheless, all fibroblast
cultures had approximately two-fold elevated PE plasmalo-
gen levels when grown in iPSC relative to fibroblast
growth media. The fact that iPSCs cannot be maintained
Table 1 Skin fibroblast and iPS cell donor information
Fibroblast ID Prior ID Status iPS cell ID# Genotype
Control1 AG05838 Healthy female,
age 36 yr,






Control2 AG09599 Healthy female,
age 30 yr,






Control3 AG13153 Healthy male,
age 30 yr,
passage 9.5 for reprogramming
Control2-iPS1 Presumed wild type
CCALD1 216212 Male CCALD patient
Age 9 yr,







CCALD2 306463 Male CCALD patient
Age 11 yr,
passage 8 for reprogramming
CCALD2-iPS1 hemizygous ABCD1
c.1847C > T; p.A616V
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Figure 1 Characterization of iPSCs from patient with CCALD. (A) Representative images of alkaline phosphatase (AP) staining and
pluripotency protein biomarker immunostaining analysis of childhood cerebral adrenoleukodystrophy (CCALD) patient induced pluripotent stem
cell (iPSCs) are presented. (B) Representative CCALD iPSCs were subject to in vitro differentiation (Materials and methods) and cell lineages
derived from all three germ layers were identified by immunostaining, as depicted. Antibodies against Tuj1, aSMA and AFP were used to
identify cells of ectodermal, mesodermal, and endodermal origin, respectively. (C) Histological analysis of teratomas derived from representative
CCALD iPSC clones from two patients is provided. Evidence of cell lineages derived from all three germ layers is provided. C, Cartilage tissue; G,
Glandular tissue; N, Neural rosettes; P, pigment neuroepithelium. Scale bar = 50 μm.
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in the undifferentiated state in fibroblast media precluded
lipid analyses under these conditions.
Differential gene expression among patient and control
cells
Among the two patient and three control fibroblasts
used for reprogramming, no differentially expressed
genes (DEGs) ( > 1.2-fold change, FDR < 0.1) were
found. This was not unexpected due to the limited
number of samples analyzed. To enhance our ability to
detect potential DEGs, we conducted a larger-scale gene
expression analysis ( > 47,000 transcripts) using cultured
skin fibroblasts from five healthy control donors and
five CCALD patients. In these studies, we identified 127
DEGs (44 with lower and 83 with higher expression in
patient relative to control fibroblasts) (Additional File 6).
Based on GeneOntology (GO) analysis, we found a
total of 13 functional categories enriched (≥ 4 genes, B-H
corrected P < 0.05) for DEGs with higher expression in
patient relative to control fibroblasts (Additional file 7).
Of these, the most specific GO category was nuclear
lumen genes. KEGG analysis did not show any enriched
categories (≥ 4 genes, B-H corrected P < 0.05) for DEGs










































































































































































































































Figure 2 The gene expression and DNA methylation profiles of fibroblasts and iPSCs. (A) A dendrogram generated based on the
unsupervised hierarchical clustering analysis of gene expression data from childhood cerebral adrenoleukodystrophy (CCALD) patient and
control fibroblasts and induced pluripotent stem cells (iPSCs) is provided. The analysis was based on data from 672 probe sets producing log2-
tranformed gene expression scores with coefficient of variation (CV) > 0.25 and conducted using average linkage and Euclidean distance; (B) A
dendrogram generated based on the unsupervised hierarchical clustering analysis of DNA methylation data from CCALD patient and control
fibroblasts and iPSCs is provided. Data from 7,493 DNA methylation assays interrogating autosomal CpG loci with CV > 0.5 and the fifth largest
and smallest b-values being > 0.6 and < 0.4, respectively, were used in this analysis in order to represent the most variable loci. Clustering was
performed using average linkage and the Pearson dissimilarity distance.
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fibroblasts. In contrast, DEGs with lower expression in
patient relative to healthy control fibroblasts were
enriched for one KEGG category (’Pathways in Cancer’ as
represented by the SMAD3, LAMA4, PML and DAPK1
genes), but no GO categories.
Given the possible gaps in public databases of gene
functions relevant to peroxisome biology and X-ALD
pathogenesis, we used the DAVID Bioinformatics
resource to annotate the function of DEGs and manually
searched for genes relevant to peroxisome biology, lipid
metabolism, oxidative stress and neuroinflammation
(Additional file 8). The only peroxisomal gene was AGPS,
which is involved in plasmalogen (a type of ether phos-
pholipid) biosynthesis, and it had higher expression in
patient fibroblasts. Nevertheless, we note that the PE plas-
malogen levels in patient and healthy control fibroblasts
were similar under both growth conditions (Figure 3C).
Two gene encoding enzymes involved in the Lands cycle,
deacylation/reacylation reactions responsible for
glycerophospholipid remodeling [43], were present with
the higher expression of LYPLA1 (deacylation), but lower
expression of MBOAT7 (reacylation), in patients relative
to control fibroblasts. Two DEGs were involved in sphin-
gosine metabolism with SMPD1, which converts sphingo-
myelin to ceramide, showing lower expression in patients
relative to control fibroblasts and SGPL1, which degrades
sphingosine-1-phosphate, showing higher expression in
patients relative to control fibroblasts. This is of interest
given the differences in the sphingolipid composition of
white matter from the brains of CCALD and healthy indi-
viduals [44]. No genes involved in classic oxidative stress
responses were found in the list. The DEGs strongly or
primarily related to neuroinflammation included CBLB,
RAB27A and TCF3, which showed higher expression in
patient fibroblasts, as well as CD81, MASP1 and GRK5,
which showed higher expression in control fibroblasts.
Based on our manual curation, we found that the iden-
tity of approximately 40% of the DEGs (46 total) were
A B
DC
Figure 3 Comparison of saturated very long chain fatty acid (sVLCFA) and plasmalogen levels in patient and healthy control
fibroblasts and iPSCs. (A) Relative sVLCFA levels in patient and healthy control fibroblasts grown in fibroblast media or iPSC media, as
represented by the C26:0/C22:0 LPC (lysophosphatidylcholine) ratio; (B) Relative sVLCFA levels in patient and healthy control iPSC clones grown
in induced pluripotent stem cell (iPSC) media, again represented by the C26:0/C22:0 LPC ratio; (C) Relative plasmalogen level in patient and
healthy control fibroblasts grown in fibroblast media and iPSC media, as represented by the total phosphatidyl ethanolamine (PE) plasmalogen/
C22:0 lysophosphatidylcholine (LPC) ratio; (D) Relative plasmalogen in patient and healthy control iPSC clones grown in iPSC media, again
represented by the total PE plasmalogen/C22:0 LPC ratio.
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consistent with the expression profiles of cultured fibro-
blasts related to the site of skin biopsy (Additional file 6).
All these genes showed the highest variability in expres-
sion based on biopsy sites, as described in reference [45].
We also note that the expression profiles of 4/6 DEGs
described above as being involved in neuroinflammation,
(RAB27A, CD81, MASP1 and GRK5), are also influenced
by the biopsy site. Although all the fibroblasts in our
study were obtained from the upper limbs, the control
and patient donor cells were collected and expanded at
different laboratories (Methods), which could influence
their gene expression signatures.
We identified 75 DEGs (22 with higher and 53 with
lower expression in patient relative to control cells)
based on the gene expression profiles of five CCALD
iPSCs from two CCALD donors and nine control iPSCs
from three healthy donors (Additional file 9). There was
no overlap with the Affymetrix probe IDs of the DEGs
uncovered in the cultured skin fibroblasts from the five
healthy controls and five CCALD patient donors dis-
cussed above. Different Affymetrix probe IDs interro-
gated the CEP57 gene indicated it was a DEG in both
systems, but in opposing directions (that is, higher in
patient relative to control fibroblasts, but higher in con-
trol relative to patient iPSCs). Based on GO analysis, we
found a total of 14 functional categories enriched (≥ 4
genes, B-H corrected P < 0.05) for DEGs with higher
expression in patient relative to control cells (Additional
file 10). These included blood vessel morphogenesis, reg-
ulation of cellular protein metabolic process and car-
boxylic acid metabolic process. In contrast, GO analysis
identified no enriched categories for DEGs with higher
expression in healthy control cells. KEGG analysis did
not identify any enriched pathways (≥ 4 genes, B-H cor-
rected P < 0.05) for DEGs with higher expression in
either the patient or control cells.
Although GO and KEGG analysis did not highlight bio-
logical processes proposed to be relevant to disease,
inspection of the DEG functions based on the DAVID
Bioinformatics resource (Additional file 11) uncovered
genes associated with major hypotheses pertinent to X-
ALD pathogenesis. Among the relevant genes with
reduced expression in CCALD patient relative to healthy
donor-derived iPSCs were PEX11B (confirmed by qPCR
in Figure 4) and CD200. The former plays a pivotal role
in peroxisome proliferation and maintenance [46,47].
Decreased CD200 expression is associated with the acti-
vation and accumulation of macrophages, including brain
microglia, and causes inflammatory responses in other
systems [48,49]. DEGs with higher expression in patient
relative to control iPSCs were also related to hypotheses
relevant to X-ALD pathogenesis and lipid metabolism.
ULK1 is the mammalian homolog of the yeast Atg1 gene,
which plays a critical role in the autophagy-mediated
turnover of peroxisomes in yeast [50]. PLA2G2A is
involved in phospholipid turnover [51]. NAAA, THBS1
and BSG all have functions related to neuroinflammation
[52-61]. SLC7A8 is a transporter of thyroid hormones,
which can induce peroxisomal biogenesis and b-oxida-
tion as well as the ABCD2 expression, whose induction
can correct biochemical functions of X-ALD patient
fibroblasts [62].
Robust differences in DNA methylation frequently found
between fibroblasts and iPSCs are not associated with
ABCD1 mutation status
In our global DNA methylation analysis (Methods), the
starting 5 fibroblasts and 14 iPSCs showed over 62,000
loci where there was a 0.25 unit difference in average b-
values and B-H corrected P < 0.05 (Additional file 12). To
focus on the most robust differentially methylated loci
(DML), we identified 744 sites that were hypomethylated
(b < 0.2) in all samples of one group and hypermethylated
(b > 0.8) in all samples in the remaining group (fibroblasts
and iPSCs). We identified 266 distinct genes proximal to
at least one DML with approximately half of them (49%)
being poorly expressed ( < 60th percentile) in all samples
regardless of its methylation status, consistent with our
prior results involving the co-analysis of DNA methylation
and gene expression profiles in normal and cancerous B-
cell populations [29,30]. Nevertheless, 60 genes (23%) were
at least modestly higher expressed when the proximal
CpG locus was in the hypomethylated relative to hyper-
methylated state ( > 1.5-fold change, FDR < 0.1 and
expressed > 60th percentile in the hypomethylated state).
In contrast, we only found five robust DMLs in compari-
sons of two patient and three control fibroblasts and one
robust DML in comparisons of five patient and nine con-
trol iPSCs (Additional file 13). The DML present in the
iPSC analysis was also present in the fibroblast analysis,
with higher methylation being found in all CCALD
patients relative to control donor cells regardless of
ABCD1 mutation status. This shared DML was proximal
to the PRDM15 gene, whose expression was not interro-
gated in our global GeneChip gene expression assays. The
remaining four DMLs in fibroblasts were proximal to the
PAX3, CCDC140, UTRN and BAIAP2 genes. All three of
the genes interrogated by our GeneChip expression assays
(PAX3, UTRN and BAIAP) were poorly expressed in all
fibroblasts regardless of ABCD1 mutation status.
Local gene expression is not substantially affected by
CNCs found in iPSCs
To begin to address the influence that CNCs present in
iPSC have on their transcriptome, we focused on the
expression profiles of genes residing in the affected
genomic regions. A total of 11 amplified segments con-
taining 22 unique genes were found in 8 iPSCs. Only six
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of these unique genes showed elevated expression in the
amplified relative to the diploid samples (that is, a >
1.2-fold increase relative to the mean expression scores
of diploid samples and falling outside their range). This
included the ID1 gene in CCALD1-3, WWC1 gene in
CCALD1-4, and IQCA1, CXCR7, SQLE and KIAA0196
genes in Control1-1.
Three iPSCs (Control2-2, Control2-4 and Control3-1)
showed evidence of having at least one genomic dele-
tion, with evidence in each case that one allele was
retained. Collectively, five unique genes were present in
the four deleted genomic regions in these iPSCs. There
was no evidence of reduced expression in the samples
with reduced copy number (that is, > 1.2-fold decrease
relative to the mean expression scores of diploid sam-
ples and falling outside their range).
Amplified or deleted segments show no differences in
DNA methylation status
A total of 745 DNA methylation assays interrogated loci
located within amplified regions present in control or
patient iPSCs. In all cases, the DNA methylation status of
such genomic regions was similar regardless of whether
it was in the diploid or amplified state. In fact, we
observed no evidence of a block of DNA methylation
change associated with a CNC (that is, three or more
contiguous assays wherein the b-value of the amplified
segment was greater than 0.2 units outside the range of
the diploid samples).
Next, we accessed the methylation status of genomic
regions subject to a loss of copy number in iPSCs. A total
of 79 DNA methylation assays interrogate loci with the
genomic regions of heterozygous deletion. The affected
Figure 4 qRT-PCR confirmation of PEX11B gene expression in patient and healthy control iPSCs. Data from the analysis of PEX11B gene
expression levels are provided. The error bars represent one standard deviation. The expression was lower in patients relative to control cells
(two-tailed Student’s t-test P-value < 0.5).
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samples included Control2-iPS2 (chr13:q14.2), Control2-
iPS4 (chr2:q33.3) and Control3-iPS1 (chr3:p14.2 and
chr5:p15.2). Again, we observed no evidence of a block of
DNA methylation change associated with a CNC (that is,
three or more contiguous assays wherein the b-value of
the deleted segment fell more than 0.2 units outside the
range of the diploid samples).
Discussion
X-ALD is a complex peroxisomal disorder with variable
expressivity. Although its primary genetic basis has been
known for some time [1-4], the exact nature of X-ALD
pathogenesis and its genetic and environmental modifiers
have not been elucidated. Here, we generated iPSC
resources for the longer-term purpose of developing novel
tissue culture models for elucidating the pathogenesis of
X-ALD and screening for more effective drug therapies. In
keeping with prior reports [63], skin fibroblasts from
ABCD1 mutation carriers can be reprogrammed to form
iPSCs with the hallmark molecular properties of pluripo-
tency, including the expression of appropriate gene and
protein biomarkers and changes in DNA methylation
levels, as summarized in Additional file 1. Patient iPSCs
could be differentiated into embryoid bodies and differen-
tiated in vitro into representative cell types of all three
germ layers. Most importantly, patient iPSCs formed tera-
tomas with evidence of cell types from all three germ
layers.
Consistent with prior reports [64-66], we identified de
novo CNCs over 10-kb in length in approximately half of
our iPSCs. These CNCs were only found in healthy
donor iPSCs and not those generated from patient cells
(Additional file 4). The observed genomic deletions
always provided evidence of affecting only one allele and
genomic amplifications always involved a limited increase
in copy number (three to four copies maximum). Due to
the fact that we conducted global expression and DNA
methylation analyses on these samples, we could investi-
gate the effects that these CNCs have on the expression
of genes located within affected genomic segments. In
almost all circumstances, their expression levels were
within the range of diploid samples. Although multiple
factors likely contribute to these observations, we favor
the explanation that this primarily reflects the effects of
selection whereby CNCs are only tolerated in iPSCs if
they involve genomic regions that do not influence
the initiation of reprogramming or maintenance of
pluripotency.
As a result of our genomic characterization of these cell
resources, we acquired global gene expression data from
patient and control fibroblasts. Many DEGs were pre-
viously reported to be associated with the site of biopsy
[45]. This is reasonable given that the patient and control
fibroblasts were acquired from different institutions even
though all biopsies involved the upper limbs of donors.
We sought to determine if there was enrichment for
functional categories or biological processes in the DEGs,
keeping in mind the limitations of using cultured cells to
study complex diseases involving interactions between
multiple organ systems. Only very broad functional cate-
gories or KEGG pathways were highlighted in these ana-
lyses, with none of them showing a direct relation to
disease.
Since there are likely to be gaps in public databases of
processes relevant to peroxisome biology and X-ALD
pathogenesis, we conducted a manual inspection of gene
annotations provided by the DAVID bioinformatics
resource and found multiple DEGs involved in immune
related processes, but only two (CBLB and RAB27A) of
these genes were not associated with the site of biopsy.
CBLB plays a critical role in antigen-induced immune
tolerance and Cblb-deficient mice immunized with mye-
lin basic protein are more susceptible to experimental
autoimmune encephalomyelitis (EAE), a model for multi-
ple sclerosis [67,68]. RAB27A mutations can lead to an
uncontrolled T lymphocyte and macrophage activation
syndrome in humans, with some individuals showing
possible leukocyte brain infiltration [69]. In one Saudi
Arabian kindred, RAB27 mutations were associated with
immunodeficiency and progressive demyelination of
brain white matter [70].
The DEGs found in patient and control iPSCs did not
overlap with those found in fibroblasts and instead were
consistent with several leading hypotheses regarding X-
ALD pathogenesis. This suggests that the reprogramming
process can minimize the confounding influence the site
of skin biopsy has on the gene expression profiles of cul-
tured fibroblasts. In particular, we highlight the reduced
expression of PEX11B, a major controller of peroxisome
proliferation and neuroinflammatory genes, in patient
relative to control iPSCs. Pex11B null mice show several
pathologic features, including neuronal migration defects,
enhanced neuronal apoptosis, developmental delay,
hypotonia and neonatal lethality [71]. Despite these
severe phenotypes, Pex11B null mice displays only mild
defects in peroxisomal fatty acid beta-oxidation and ether
lipid biosynthesis [71]. Intriguingly, the deletion of a sin-
gle Pex11B allele leads to a slightly increased number of
peroxisomes, increased levels of oxidative stress in brain
tissue, and neuronal cell death in mice [72]. In addition,
the ULK1, whose yeast homolog plays a critical role in
the autophagy-mediated peroxisome turnover [50],
showed higher expression in CCALD patient relative to
control iPSCs. It is tempting to speculate that if nervous
and immune system cells of ABCD1 mutation carriers
indeed have aberrant PEX11B and ULK1 activity, this
could lead to differences in peroxisome abundance and/
or activity that increase reactive oxygen species (ROS)
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levels and promote X-ALD pathogenesis. It remains to be
determined if ABCD1 mutation carriers have abnormal
peroxisome abundance in their pertinent nervous and
immune system cells and tissues.
In a similar vein, the increased NAAA, THBS1, BSG
(aka CD147 aka EMMPRIN) and NOTCH1 gene expres-
sion in patients relative to control iPSCs is supportive of
hypotheses regarding a predisposition to neuroinflam-
mation that is a prelude to devastating autoimmune
responses. NAAA hydrolyzes palmitoylethanolamide
(PEA), a naturally occurring lipid amide that, when
administered as a drug, inhibits inflammatory responses
[56]. In principle, increasing leukocyte NAAA levels
could reduce PEA levels and promote inflammation. In
fact, a chemical inhibitor of NAAA function attenuates
inflammation and tissue damage and improves recovery
of motor function in mice with spinal cord trauma [56].
Intriguingly, CD200 has been proposed to play a role in
the immune privileged status of the CNS when CD200-
mediated immune suppression occurs via neuron-micro-
glial as well as glial-glial interactions in inflammatory
conditions [73]. THBS1 is linked to neuroinflammatory
processes involving astrocyte and microglia through its
role in processing and activating the TGF-b ligand [74]
and is also implicated in responses to oxidative stress
[75]. Likewise, Notch1 is involved in microglial asso-
ciated inflammation [76]. Also of relevance are emerging
reports that BSG acts a master regulator of matrix
metalloproteinases (MMP) implicated in most diseases
involving neuroinflammation and thus has been pro-
posed to play a role in the immune-privileged status of
the CNS [77].
Although we highlight the possible implications of the
gene expression profiles observed in patient iPSCs, we
note alternative hypotheses regarding their origins and
biological significance. While the iPSCs described in this
study have the hallmark properties of pluripotency, their
gene expression profiles could reflect subtle ABCD1
mutation status-dependent differences in their predispo-
sition to differentiate into specific cell types and
lineages. Comparisons of the gene expression profiles of
mature cell types derived from patient- and healthy
donor-derived iPSCs will be especially informative. The
persistence or elimination of groups of DEGs reflective
of biological processes and pathways could provide a
means of assessing the tissue specificity of disease and
enhance the ability to discern biologically informative
gene expression signatures from noise resulting from
confounding variables, such as tissue culture conditions.
Although ABCD1 mutation carriers show elevated
sVLCFA levels in their blood and urine and reduced
sVLCFA catabolic activity in their cultured fibroblasts,
the role of sVLCFA in disease pathogenesis is still under
discussion. The significance of decreased plasmalogen
levels in the patients’ brain white matter also is unclear
[44,78]. As expected, CCALD patient fibroblasts had ele-
vated VLCFA levels, but similar PE plasmalogen levels,
relative to those from healthy donors (Figure 3A, C).
Likewise, iPSCs from CCALD patient and healthy control
donors also showed similar PE plasmalogen levels (Figure
3D). The fact that all patient and control iPSCs tested
had low VLCFA levels, based on C26:0-lysophosphoryl-
choline measurements, (Figure 3B) is puzzling, yet con-
sistent with prior reports [63]. VLCFA levels are
determined by their rate of synthesis (that is, catalyzed by
fatty acid elongating enzyme ELOVL1 [79]), degradation
(affected by ABCD1 and ABCD2 function [80]) and
uptake of these fatty acids from the culture medium. As
such, one hypothesis is that the rate of VLCFA synthesis
is lower in iPSCs relative to fibroblasts under the culture
conditions evaluated. Consistent with this hypothesis and
prior reports [63], the expression of the ELOVL1 gene
was significantly lower (2.6-fold, FDR < 2.2 × 10-9) in
iPSCs relative to fibroblasts. Nevertheless, we note that
ELOVL1 was not differentially expressed in patient rela-
tive to control fibroblasts or iPSCs. An alternate hypoth-
esis that the ABCD2 gene is compensating for the
impaired ABCD1 function in patient iPSCs; however,
ABCD2 was not differentially expressed in patient relative
to control fibroblasts or iPSCs. This does not preclude
the possibilities that ABCD2 activity is being increased
on the protein level or that another gene is playing a
major role in significantly lowering VLCFA levels in
CCALD iPSCs. We also note a prior hypothesis that the
rapid growth rate of iPSCs could reduce their VLCFA
levels, independent of their ABCD1 mutation status [63].
Fibroblasts have altered morphology and slowed growth
in iPSC media relative to fibroblast media, which accord-
ing to the growth rate hypothesis could contribute to
their reduced VLCFA levels. Given that iPSCs can rapidly
differentiate in fibroblast media, iPSC growth media pro-
vides an imperfect, but necessary, compromise in direct
comparisons between cultured fibroblasts and iPSCs. We
note the potential contribution of MEF feeder cells to
iPSC lipid profiles and the advantages of using feeder-
free media in future experiments.
Future applications and directions
The impending implementation of newborn screening for
X-ALD based on blood lipid profiles will increase the
demand for model systems to screen for more effective
therapeutic interventions [36,81]. Early detection would
provide physicians with a window of opportunity to treat
presymptomatic patients prior to the development of
CCALD, and may also prevent or delay AMN onset.
Therapeutic interventions, such as Lorenzo’s Oil, help
prevent the onset of cerebral disease in some individuals,
but are not effective for the majority of CCALD patients
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and, likewise, there are no effective options for AMN
[75-77]. A compelling attribute of iPSC model systems is
that they represent the exact ABCD1 mutations found in
the patient population and thus provide an opportunity
to test therapeutic agents tailored to a patient’s genotype
in cell populations most affected by disease. Examples of
genotype-dependent therapeutic strategies include non-
sense suppressor drugs [33] and molecular chaperones
[82] for individuals with nonsense and missense muta-
tions, respectively.
The fact that CCALD iPSCs show gene expression pro-
files similar to those derived from healthy controls may
reflect the fact that X-ALD clinical symptoms do not
manifest at birth but, instead, occur in early childhood or
later in life. Given that ABCD1 mutant mice show clinical
aspects of X-ALD with increasing age [83], it is possible
that later passage CCALD iPSCs and their derivatives
may manifest gene expression profiles and/or functional
properties more consistent with disease pathogenesis and
progression. In this regard, a comparison of the proper-
ties of iPSCs and their derivatives previously obtained
from other CCALD and AMN patients [63] as a function
of in vitro passage number could be informative. Despite
the promise of iPSC approaches, it will remain a signifi-
cant challenge to generate and optimize in vitro model
systems for X-ALD and other complex disorders that
involve multiple organ systems as well as unknown gene-
environment interactions and genetic modifiers.
Conclusions
We have reprogrammed skin fibroblasts from CCALD
patients and control donor primary fibroblasts into
iPSCs that show all the fundamental hallmark molecular
and cellular properties of pluripotency. The DEGs found
in comparisons of patient- and healthy donor-derived
iPSCs are consistent with emerging hypotheses regard-
ing the role of peroxisomes, oxidative stress and neu-
roinflammation in the pathogenesis of X-ALD. Given
that the sVLFCA profiles of the patient iPSCs are simi-
lar to those of control iPSCs, these gene expression pro-
files are not dependent on the presence of the hallmark
lipid biomarkers of disease. Additional gene expression
and functional analyses involving differentiated cell
types derived from CCALD and control iPSCs could be
especially informative given our preliminary results. This
would include cell types related to the CNS (for exam-
ple, oligodendrocytes, astrocytes and microglia), adreno-
cortical and male reproductive (for example, Leydig and
Sertoli cells) aspects of disease. Furthermore, investiga-
tions involving patient tissue samples and animal models
are required in order to determine if the observed fibro-
blast and iPSC gene expression profiles are reflective of
pathogenic mechanisms or are simply specific to our
cultured cells.
Additional material
Additional file 1: Characterization of candidate induced pluripotent
stem cells (iPSCs). A complete listing of the protein, genetic, epigenetic,
and cell differentiation assays performed on the iPSCs described in this
study is provided.
Additional file 2: Log-transformed gene expression scores from
childhood cerebral adrenoleukodystrophy (CCALD) patient and
healthy donor control fibroblasts and induced pluripotent stem
cells (iPSCs). A complete list of log-transformed gene expression scores
from CCALD patient and healthy donor control fibroblasts and iPSCs is
provided.
Additional file 3: DNA methylation assay beta-values from
childhood cerebral adrenoleukodystrophy (CCALD) patient and
healthy donor control fibroblasts and induced pluripotent stem
cells (iPSCs). A partial list of DNA methylation assay beta-values from
CCALD patient and healthy donor control fibroblasts and iPSCs is
provided.
Additional file 4: Molecular karyotyping analysis of induced
pluripotent stem cells (iPSCs). A full list of copy number changes
detected in the iPSCs described in this study is provided.
Additional file 5: Hierarchical clustering analysis gene expression
data from childhood cerebral adrenoleukodystrophy (CCALD)
patient and control fibroblasts and induced pluripotent stem cells
(iPSCs) based on pluripotency genes. The analysis was based on gene
expression data from 30 pluripotency genes reported in reference [41]
and performed with average-linkage and Euclidean distance.
Additional file 6: Differential gene expression between childhood
cerebral adrenoleukodystrophy (CCALD) patient and healthy donor
control fibroblasts. A complete list of all gene expression scores and
differentially expressed genes (DEGs) between CCALD patient and
healthy donor control fibroblasts is provided.
Additional file 7: Gene Ontology (GO) analysis of differentially
expressed genes (DEGs) between childhood cerebral
adrenoleukodystrophy (CCALD) patient and healthy donor control
fibroblasts. GO analysis of DEGs between CCALD patient and healthy
donor control fibroblasts is provided.
Additional file 8: The Database for Annotation, Visualization and
Integrated Discovery (DAVID) annotation of differentially expressed
genes (DEGs) found in childhood cerebral adrenoleukodystrophy
(CCALD) patient and control donor fibroblasts. DAVID annotation of
DEGs found in CCALD patient and control donor fibroblasts is provided.
Additional file 9: Differential gene expression between childhood
cerebral adrenoleukodystrophy (CCALD) patient and healthy donor
control iPSCs. A complete list of differentially expressed genes (DEGs)
between CCALD patient and healthy donor control induced pluripotent
stem cells (iPSCs) is provided.
Additional file 10: Gene Ontology (GO) analysis of differentially
expressed genes (DEGs) between childhood cerebral
adrenoleukodystrophy (CCALD) patient and healthy donor control
induced pluripotent stem cells (iPSCs). GO analysis of DEGs between
CCALD patient and healthy donor control iPSCs is provided.
Additional file 11: Database for Annotation, Visualization and
Integrated Discovery (DAVID) annotation of differentially expressed
genes (DEGs) found in childhood cerebral adrenoleukodystrophy
(CCALD) patient and control donor induced pluripotent stem cells
(iPSCs). DAVID annotation of DEGs found in CCALD patient and control
donor iPSCs is provided.
Additional file 12: Differentially methylated loci (DML) between
fibroblasts and induced pluripotent stem cells (iPSCs). A complete
list of DML between fibroblasts and iPSCs is provided.
Additional file 13: Differentially methylated loci (DML) between
patient and control fibroblasts and induced pluripotent stem cells
(iPSCs). A complete list of DML between patient and control fibroblasts
and iPSCs is provided.
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